Join Growin Stock Community!

Ensysce biosciences, inc.ENSC.US Overview

US StockHealthcare
(No presentation for ENSC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ENSC AI Insights

ENSC Overall Performance

ENSC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ENSC Recent Performance

-28.24%

Ensysce biosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ENSC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ENSC Key Information

ENSC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ENSC Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Price of ENSC

ENSC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ENSC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.63
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.50
PB Ratio
1.19
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.63
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.50
PB Ratio
1.19
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ENSC's latest earnings report released?

    The most recent financial report for Ensysce biosciences, inc. (ENSC) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ENSC's short-term business performance and financial health. For the latest updates on ENSC's earnings releases, visit this page regularly.

  • How much cash does ENSC have?

    At the end of the period, Ensysce biosciences, inc. (ENSC) held Total Cash and Cash Equivalents of 1.67M, accounting for 0.53 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ENSC's EPS continuing to grow?

    According to the past four quarterly reports, Ensysce biosciences, inc. (ENSC)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.29. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ENSC?

    Ensysce biosciences, inc. (ENSC)'s Free Cash Flow (FCF) for the period is -1.87M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 82.9% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.